Figure 6.

Yoda1 increased Rb uptake to a similar degree in the presence or absence (control) of the NKCC inhibitor bumetanide (1 µM). (Panel A) shows Rb uptake in cells exposed to Yoda1 (1 µM) in Rb-containing Krebs solution ± bumetanide for 10 min. Added alone, bumetanide slightly reduced Rb uptake, but not to a significant degree. (Panel B) shows the bumetanide-sensitive component of Rb uptake. The values are the mean ± SEM of results from 6 independent experiments. ** and *** indicate significant differences (p < 0.01 and p < 0.001, respectively) from the control (no Yoda1), as determined by one-way ANOVA followed by Šídák’s multiple comparison test. NS = not significant.